[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370206-105":59,"doc-detail-370206-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ulacnet-301-optimo-protocol-hpv-vaccination-regimen-optimization-for-cancer-prevention-in-children-and-adolescents-living-with-hiv","ULACNet-301, OPTIMO protocol - HPV vaccination regimen optimization for cancer prevention in children and adolescents living with HIV","","Persistent human papillomavirus (HPV) infection is linked to most cervical and anal cancers and a substantial share of other anogenital and oropharyngeal malignancies. Although prophylactic HPV vaccines prevent HPV infection and related disease, vaccine responses can be reduced in individuals living with HIV. The OPTIMO study compares immune responses in children and adolescents with HIV receiving 1, 2, or 3 doses of the 9-valent HPV vaccine versus a single-dose group without HIV, assessing durability 24 months after the final dose.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ulacnet-301-optimo-protocol-hpv-vaccination-regimen-optimization-for-cancer-prevention-in-children-and-adolescents-living-with-hiv/370206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ulacnet-301-optimo-protocol-hpv-vaccination-regimen-optimization-for-cancer-prevention-in-children-and-adolescents-living-with-hiv/370206.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the OPTIMO study address regarding HPV vaccination and HIV?","Question",{"text":113,"@type":114},"Evidence suggests reduced HPV vaccine responses in individuals living with HIV, and there is limited data comparing immune responses after 1 dose versus 2–3 doses in this population. OPTIMO directly evaluates these dose regimens.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the OPTIMO study compare vaccination schedules?",{"text":118,"@type":114},"Children and adolescents living with HIV receive 1, 2, or 3 doses of the 9-valent HPV (9vHPV) vaccine, while children without HIV receive a single dose as a comparison group.",{"name":120,"@type":111,"acceptedAnswer":121},"When is response durability assessed in OPTIMO?",{"text":122,"@type":114},"Durability of the immune response is assessed at 24 months after the last dose of each vaccination regimen.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370206,1790506118,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Pinto-Santini et al. BMC Cancer (2025) 25:151 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-13551-z](https://doi.org/10.1186/s12885-025-13551-z)  \nSTUDY PROTOCOL Open Access  \nULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV  \nDelia Pinto-Santini 1, Emilia M. Jalil2, Giovana Teixeira Fernandes2, Genevieve Hilaire4, Lenka Kolevic3, Robinson Cabello3, Beatriz Grinsztejn2, William Pape4, Marie Marcel le Deschamps4, Margaret G. House5, Emma Brofsky5, VikrantV. Sahasrabuddhe5, Sayan Dasgupta 1, Siavash Pasalar 1, Margaret M. Madeleine 1, Joseph Carter 1, Priya R. Prabhu 1, Denise Galloway 1 and Ann Duerr 1*  \nAbstract  \nBackground Persistent infection with human papillomavirus (HPV) is associated with most cervical and anal cancer cases and a large fraction of other anogenital and oropharyngeal cancers. The prophylactic HPV vaccines are known to prevent HPV infections and HPV-associated disease, although there is evidence of reduced response to the HPV vaccination among individuals living with HIV. Prior studies among individuals without HIV suggest that a single HPV vaccine dose induces humoral immune responses that, while lower than those induced by two or three doses, still confer protection against HPV infection. Current recommendations for HPV vaccine include a single-dose schedule for children 9–14-years-olds without HIV. Although two to three doses are recommended for children living with HIV (CLWH), there is very limited data comparing responses to one vs. 2–3 doses in CLWH.  \nMethods The OPTIMO study will compare immune responses to HPV vaccination in CLWH by measuring antibody and memory B cell (Bmem) responses after 1, 2, or 3 doses ofthe 9-valent HPV (9vHPV) vaccine, Gardasil-9 . A comparison group of children without HIV will receive one dose of the vaccine. The durability of the response will be assessed at 24 months after the last dose of a given regimen. The OPTIMO trial will take place among CLWH from low and middle-income country (LMIC) settings in Peru, Brazil, and Haiti.  \nDiscussion Previous studies of single-dose regimens in individuals without HIV raise questions about whether one dose would suffice for CLWH and, if not, whether two or three doses are needed to provide protection against HPVrelated cancers. These questions have operational consequences in LMICs given the barriers to delivering multiple doses, uneven availability, and intermittent shortages of HPV vaccines. In addition, information on HIV status forchildren and adolescents is rarely available during vaccination campaigns based in schools or public health clinics, so CLWH may receive a single dose despite policy recommendations that they receive two or three. This study will  \n*Correspondence: Ann Duerr[aduerr@fredhutch.org](aduerr@fredhutch.org)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)ice","cbCaitTLZ63SxXHX","https://ap.wps.com/l/cbCaitTLZ63SxXHX","pdf",1561661,"English","# Abstract\n## Background\n## Methods\n## Discussion\n## Trial registration\n# Keywords\n# Background","[{\"question\":\"What problem does the OPTIMO study address regarding HPV vaccination and HIV?\",\"answer\":\"Evidence suggests reduced HPV vaccine responses in individuals living with HIV, and there is limited data comparing immune responses after 1 dose versus 2–3 doses in this population. OPTIMO directly evaluates these dose regimens.\"},{\"question\":\"How does the OPTIMO study compare vaccination schedules?\",\"answer\":\"Children and adolescents living with HIV receive 1, 2, or 3 doses of the 9-valent HPV (9vHPV) vaccine, while children without HIV receive a single dose as a comparison group.\"},{\"question\":\"When is response durability assessed in OPTIMO?\",\"answer\":\"Durability of the immune response is assessed at 24 months after the last dose of each vaccination regimen.\"}]","ULACNet-301, OPTIMO protocol - HPV vaccination regimen optimization for cancer prevention in children and adolescents living with HIV | PDF",1790187348,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ef725d2ebcb520a483d25f22415704f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8ecf4169bb281059da8c4d658153085.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/191aff2e0fee9d923893f2c3060dbda5.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf645f09d6f1e7ddf89d085cbf60d23c.webp",980,1306]